curr gastroenterol rep 2017 19 6 doi 10.1007s11894-017-0546-0the enigmatic gut in cystic fibrosis linking inflammation dysbiosis and the increased risk of malignancymillie garg1  chee y. ooi12published online 2 february 2017 springer sciencebusiness media new york 2017abstractpurpose of review intestinal inflammation dysbiosis and in- creased gastrointestinal malignancy risks are well-described in patients with cystic fibrosis cf.

murine studies suggest the cf gene cystic fibrosis transmembrane conductance regulator cftr gene itself may be a tumour suppressor gene.summary the pathophysiology of interactions among intesti- nal inflammation dysbiosis and malignancy in cf is not clearly understood and requires further research.this article is part of the topical collection on pediatric gastroenterology chee y. ooi 1 school of women's and children's health medicine university of new south wales randwick nsw 2031 australia2 department of paediatric gastroenterology sydney children's hospital randwick nsw 2031 australiakeywords cystic fibrosis .

2016354179-87. doi.gottlieb ra dosanjh a. mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in c127 cells possible relevance to cystic fibrosis.

clinical mechanism of the cystic fibrosis trans- membrane conductance regulator potentiator ivacaftor in g551d- mediated cystic fibrosis.

comparison of the clinical manifesta- tions of cystic fibrosis in black and white patients.

cancer risk in nontransplanted and transplanted cystic fibrosis patients a 10-year study.

the risk of cancer among patients with cystic fibrosis.

20091192613-22. doi.gelfond d ma c semler j borowitz d. intestinal ph and gastro- intestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule.

gastrointestinal transit times and motility in patients with cystic fibrosis.

199639985-91.duytschaever g huys g boulanger l de boeck k vandamme p. amoxicillin-clavulanic acid resistance in fecal enterobacteriaceae from patients with cystic fibrosis and healthy siblings.

evidence of intestinal inflammation in patients with cystic fibrosis.

evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients.

faecal proteomics a tool to investigate dysbiosis and inflammation in patients with cystic fibrosis.

the effect of probiotics on fecal calprotectin in patients with cystic fibrosis.

improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a lactobacillus reuteri probiotic preparation a double blind prospective study.

